Lung Cancer
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
- Details
ClinicalTrials.gov ID:
NCT03596866
Diagnosis Type:
NA
USOR Number:
- Address
2800 Highway 75 North
Sherman, TX 75090
P: (903) 868-4700